Project Details
Description
A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician s Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)- altered, Chemotherapy- and FGFR Inhibitor-Refracto
| Status | Active |
|---|---|
| Effective start/end date | 2/26/24 → 2/28/34 |
Funding
- TRANSTHERA SCIENCES (NANJING), INC.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.